Condition: Tuberculosis · Sponsor: University of California, San Francisco
As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.
This description comes directly from the study's public registry record.
Adithya Cattamanchi, MD · 415-206-5489 · adithya.cattamanchi@ucsf.edu
Sophie Huddart, PhD · Sophie.Huddart@ucsf.edu
Always discuss trial participation with your own doctor first.
| Kisenyi Health Center | Kampala, Uganda | Recruiting |
| Mulago Outpatient Department | Kampala, Uganda | Recruiting |
| Hanoi Lung Hospital, Outpatient departments | Hanoi, Vietnam | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07018076